公开(公告)号：US20220315582A1

公开(公告)日：2022-10-06

申请号：US16973836

申请日：2020-07-31

Applicant: Novartis AG

Inventor： Chris ADAIR ,  Tracy CHEN ,  Jian DING ,  Christy FRYER ,  Yuko ISOME ,  Marie-Helene LARRAUFIE ,  Katsumasa NAKAJIMA ,  Nik SAVAGE ,  Ariel Sterling TWOMEY

IPC: C07D471/10 ,  A61P35/00

Abstract: The present invention relates to novel tricyclic compounds that are AKR1C3 dependent KARS inhibitor, processes for their preparation, pharmaceutical compositions, and medicaments containing them, and their use in diseases and disorders mediated by an AKR1C3 dependent KARS inhibitor.

公开(公告)号：US20240262827A1

公开(公告)日：2024-08-08

申请号：US18594323

申请日：2024-03-04

Applicant: NOVARTIS AG

Inventor： Chris ADAIR ,  Tracy CHEN ,  Jian DING ,  Christy FRYER ,  Yuko ISOME ,  Marie-Helene LARRAUFIE ,  Katsumasa NAKAJIMA ,  Nik SAVAGE ,  Ariel Sterling TWOMEY

IPC: C07D471/10 ,  A61K31/4747 ,  A61P35/00

CPC classification number: C07D471/10 ,  A61P35/00 ,  A61K31/4747

Abstract: The present invention relates to novel tricyclic compounds that are AKR1C3 dependent KARS inhibitor, processes for their preparation, pharmaceutical compositions, and medicaments containing them, and their use in diseases and disorders mediated by an AKR1C3 dependent KARS inhibitor.

公开(公告)号：US20230091510A1

公开(公告)日：2023-03-23

申请号：US17612280

申请日：2020-05-19

Applicant: Novartis AG

Inventor： Zhuoliang CHEN ,  Katsumasa NAKAJIMA ,  Matthew T. BURGER ,  Joseph Anthony D'ALESSIO ,  Eric MCNEILL ,  Mark G, PALMERO ,  Bing YU ,  Qiang ZHANG

IPC: A61K47/68 ,  A61K47/54 ,  A61K47/60 ,  A61K47/61 ,  A61P35/00 ,  C07K16/28 ,  C07K5/062

Abstract: Provided herein are linkers, linker-drug groups and anti-body-drug conjugates comprising hydrophilic groups.

公开(公告)号：US20210323956A1

公开(公告)日：2021-10-21

申请号：US17268512

申请日：2019-08-12

Applicant: Novartis AG

Inventor： Christopher ADAIR ,  Katsumasa NAKAJIMA ,  Rukundo NTAGANDA ,  Julien PAPILLON ,  Troy Douglas SMITH

IPC: C07D417/12 ,  A61K45/06

Abstract: A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a BRM-mediated and/or BRG1-mediated disease or disorder: Formula (I) wherein R1 through R6 are as defined herein.

公开(公告)号：US20190100752A1

公开(公告)日：2019-04-04

申请号：US16083327

申请日：2017-03-08

Applicant: Novartis AG

Inventor： Shari Lynn CAPLAN ,  Katsumasa NAKAJIMA

IPC: C12N15/11 ,  C07H21/02 ,  C12N15/87

Abstract: This invention provides messenger RNA (mRNA) molecules comprising an open reading frame that encodes a protein of interest, wherein said modified RNA comprises a modified nucleoside selected from the group consisting of: (I), (II), and (III), gene therapy vectors comprising same, methods of synthesizing same, and methods for gene replacement, gene therapy, gene transcription silencing, and the delivery of therapeutic proteins to tissue in vivo, comprising the molecules. The present invention also provides methods of reducing the immunogenicity of mRNA molecules.